期刊
NATURE NANOTECHNOLOGY
卷 14, 期 11, 页码 1007-1017出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41565-019-0567-y
关键词
-
资金
- Netherlands Organization for Scientific Research (NWO
- Veni STW) [14385]
- Central Norway Regional Health Authority [46084000]
- European Union (European Fund for Regional Development: I3-STM) [0800387]
- German Research Foundation (DFG) [GRK 2375, 331065168, SFB1066, SFB/TRR57]
- National Institutes of Health [R01 HL118440, R01 HL125703, P01 HL131478]
- Netherlands Organization for Scientific Research (NWO
- ZonMW Vici grant) [016.176.622]
- European Research Council [309495, 680882, 813086]
- European Commission (ERA-NET: NSC4DIPG)
- Aachen Interdisciplinary Center for Clinical Research (IZKF) [O3-2]
- European Research Council (ERC) [309495, 680882, 813086] Funding Source: European Research Council (ERC)
Nanomedicines are extensively employed in cancer therapy. We here propose four strategic directions to improve nanomedicine translation and exploitation. (1) Patient stratification has become common practice in oncology drug development. Accordingly, probes and protocols for patient stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclusion in clinical trials. (2) Rational drug selection is crucial for clinical and commercial success. Opportunistic choices based on drug availability should be replaced by investments in modular (pro)drug and nanocarrier design. (3) Combination therapies are the mainstay of clinical cancer care. Nanomedicines synergize with pharmacological and physical co-treatments, and should be increasingly integrated in multimodal combination therapy regimens. (4) Immunotherapy is revolutionizing the treatment of cancer. Nanomedicines can modulate the behaviour of myeloid and lymphoid cells, thereby empowering anticancer immunity and immunotherapy efficacy. Alone and especially together, these four directions will fuel and foster the development of successful cancer nanomedicine therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据